Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dermatology in Graft-Versus-Host Disease: Diagnosis, Differential, and Management After Transplant
Description
The talk emphasized the important role dermatologists play in caring for transplant patients, especially in diagnosing and differentiating graft-versus-host disease (GVHD) from common mimickers. It reviewed basic transplant concepts, including allogeneic transplant, conditioning regimens, and GVHD risk factors such as HLA mismatch and reduced-intensity conditioning. Acute GVHD was described as an immune reaction in which donor T cells attack host tissues, classically affecting skin and gut; skin findings are often morbilliform, folliculocentric, acral-predominant, and may be pruritic or burning, with severity staged by body surface area and blistering/desquamation. Management ranges from topical steroids and calcineurin inhibitors to systemic steroids, ruxolitinib, sirolimus, UVB, and extracorporeal photopheresis for more severe disease. A major focus was the differential diagnosis in the early post-transplant period, including toxic erythema of chemotherapy, Grover-like transient acantholytic dermatosis, and demodex dermatitis, all of which can resemble GVHD but have distinguishing clues such as timing, distribution, follicular or facial involvement, asymptomatic presentations, or cut-off signs. The talk also noted that biopsy can help rule in alternative diagnoses but often cannot reliably separate GVHD from a morbilliform eruption. Finally, it highlighted medication-related eruptions such as ponatinib-associated rashes, which can further complicate assessment in the post-transplant setting.
View moreConclusions
- Cutaneous GVHD is a key post-transplant diagnosis that dermatologists are well positioned to detect, stage, and help manage because morphology and distribution are central to distinguishing it from mimickers.
- Acute GVHD classically presents as a morbilliform, often folliculocentric eruption with acral predominance, and it commonly accompanies gut and liver involvement.
- The strongest risk factor for GVHD is donor-recipient HLA mismatch, with additional risk from allogeneic grafts, unrelated or haploidentical donors, peripheral blood grafts, and less intensive conditioning regimens.
- The timing after transplant is one of the most useful clues: acute GVHD is more likely to appear later in the first month, while engraftment syndrome, eruption of lymphocyte recovery, and toxic erythema of chemotherapy tend to occur earlier.
- Biopsy can sometimes help rule in alternative diagnoses, but it does not reliably distinguish GVHD from other morbilliform eruptions on histology alone.
- Toxic erythema of chemotherapy is an important mimic because it can involve acral skin but usually has more intertriginous involvement and a more chemo-timed onset.
- Grover’s-like disease after transplant is a common, often self-limited, and sometimes asymptomatic mimic that can occur in atypical locations and is usually treated topically rather than with systemic immunosuppression.
- Demodex dermatitis commonly appears during immune reconstitution and tapering of immunosuppression, is notably pruritic with a sharp facial cutoff, and should be treated with anti-demodex measures rather than reflex systemic steroids.
- A GVHD-like inflammatory reaction to Demodex can occur but is usually mild and self-limited.
- Post-transplant medications such as ponatinib can cause diverse rashes that may resemble GVHD and must be considered in the differential.
- Overall, careful attention to distribution, symptom pattern, transplant timeline, and medication exposure is essential to avoid misdiagnosing GVHD and overtreating non-GVHD rashes.
- Bashir Q, Shpall EJ, Champlin RE. Manual of Hematopoietic Cell Transplantation and Cellular Therapies.#10.1002/9781119000822.hfcm071.pub2
- Ghimire et al. Front Immunol. 2017;8:79.
- Harris et al., Biology of Blood and Marrow Transplantation, 2016.
- NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation. Version 3.2025.
- Harvell et al. Am J Dermatopathol. 1998.
- Calhoun et al. Int J Dermatol. 2022 08;61(8):e299-e301.
- Cynthia Chen, JAAD Case Rep. 2018 Nov 14;4(10):1055-1058.